NO300114B1 - Fremgangsmåte for fremstilling av et vandig suspensjonspreparat for injeksjon - Google Patents
Fremgangsmåte for fremstilling av et vandig suspensjonspreparat for injeksjon Download PDFInfo
- Publication number
- NO300114B1 NO300114B1 NO923429A NO923429A NO300114B1 NO 300114 B1 NO300114 B1 NO 300114B1 NO 923429 A NO923429 A NO 923429A NO 923429 A NO923429 A NO 923429A NO 300114 B1 NO300114 B1 NO 300114B1
- Authority
- NO
- Norway
- Prior art keywords
- water
- less
- local anesthetic
- insoluble
- weight
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000007900 aqueous suspension Substances 0.000 title claims abstract description 17
- 238000002347 injection Methods 0.000 title claims abstract description 9
- 239000007924 injection Substances 0.000 title claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 title abstract description 6
- 239000002245 particle Substances 0.000 claims abstract description 30
- 239000003589 local anesthetic agent Substances 0.000 claims abstract description 25
- 208000002193 Pain Diseases 0.000 claims abstract description 21
- 230000036407 pain Effects 0.000 claims abstract description 20
- 239000004084 narcotic analgesic agent Substances 0.000 claims abstract description 5
- 239000000725 suspension Substances 0.000 claims description 42
- 238000000034 method Methods 0.000 claims description 17
- 230000003533 narcotic effect Effects 0.000 claims description 15
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 14
- 229920000053 polysorbate 80 Polymers 0.000 claims description 14
- 239000012736 aqueous medium Substances 0.000 claims description 13
- 239000002736 nonionic surfactant Substances 0.000 claims description 13
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 13
- 229940068968 polysorbate 80 Drugs 0.000 claims description 12
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 229940124641 pain reliever Drugs 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 6
- 229960004050 aminobenzoic acid Drugs 0.000 claims description 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 150000001298 alcohols Chemical class 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 150000002148 esters Chemical class 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 3
- 238000010257 thawing Methods 0.000 claims description 3
- 125000005907 alkyl ester group Chemical group 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 150000002170 ethers Chemical class 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 239000013543 active substance Substances 0.000 abstract description 9
- 238000007913 intrathecal administration Methods 0.000 abstract description 3
- 239000004094 surface-active agent Substances 0.000 abstract description 2
- 206010002091 Anaesthesia Diseases 0.000 abstract 2
- 230000037005 anaesthesia Effects 0.000 abstract 2
- 230000008595 infiltration Effects 0.000 abstract 1
- 238000001764 infiltration Methods 0.000 abstract 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 229960005181 morphine Drugs 0.000 description 11
- 239000003708 ampul Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000002202 Polyethylene glycol Substances 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000003193 general anesthetic agent Substances 0.000 description 6
- 229960005015 local anesthetics Drugs 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229940035676 analgesics Drugs 0.000 description 5
- 229940035674 anesthetics Drugs 0.000 description 5
- 239000000730 antalgic agent Substances 0.000 description 5
- 239000000375 suspending agent Substances 0.000 description 5
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 4
- 229920001214 Polysorbate 60 Polymers 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 230000003444 anaesthetic effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- BLFLLBZGZJTVJG-UHFFFAOYSA-N ethyl ester of p-aminobenzoic acid Natural products CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 3
- 229940113124 polysorbate 60 Drugs 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000278 spinal cord Anatomy 0.000 description 2
- 210000000273 spinal nerve root Anatomy 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- ONPGOSVDVDPBCY-CQSZACIVSA-N 6-amino-5-[(1r)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-n-[4-(4-methylpiperazine-1-carbonyl)phenyl]pyridazine-3-carboxamide Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NN=1)N)=CC=1C(=O)NC(C=C1)=CC=C1C(=O)N1CCN(C)CC1 ONPGOSVDVDPBCY-CQSZACIVSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 229920001219 Polysorbate 40 Polymers 0.000 description 1
- 229920002651 Polysorbate 85 Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 1
- 229960001736 buprenorphine Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RKHQGWMMUURILY-UHRZLXHJSA-N cortivazol Chemical compound C([C@H]1[C@@H]2C[C@H]([C@]([C@@]2(C)C[C@H](O)[C@@H]1[C@@]1(C)C2)(O)C(=O)COC(C)=O)C)=C(C)C1=CC1=C2C=NN1C1=CC=CC=C1 RKHQGWMMUURILY-UHRZLXHJSA-N 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002988 lumbosacral plexus Anatomy 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-N picric acid Chemical class OC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-N 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113171 polysorbate 85 Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Anesthesiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NL9000634A NL9000634A (nl) | 1990-03-20 | 1990-03-20 | Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding. |
| PCT/NL1991/000042 WO1991014455A1 (en) | 1990-03-20 | 1991-03-20 | Aqueous suspension preparation for injection, method for producing the same and use thereof for producing pain relief |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO923429D0 NO923429D0 (no) | 1992-09-03 |
| NO923429L NO923429L (no) | 1992-09-17 |
| NO300114B1 true NO300114B1 (no) | 1997-04-14 |
Family
ID=19856770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO923429A NO300114B1 (no) | 1990-03-20 | 1992-09-03 | Fremgangsmåte for fremstilling av et vandig suspensjonspreparat for injeksjon |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5346903A (fi) |
| EP (1) | EP0521070B1 (fi) |
| JP (1) | JPH05507466A (fi) |
| AT (1) | ATE121631T1 (fi) |
| AU (1) | AU646857B2 (fi) |
| BR (1) | BR1100601A (fi) |
| CA (1) | CA2077641C (fi) |
| DE (1) | DE69109279T2 (fi) |
| DK (1) | DK0521070T3 (fi) |
| ES (1) | ES2074269T3 (fi) |
| FI (1) | FI98890C (fi) |
| GR (1) | GR3015940T3 (fi) |
| NL (1) | NL9000634A (fi) |
| NO (1) | NO300114B1 (fi) |
| WO (1) | WO1991014455A1 (fi) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5206267A (en) * | 1991-05-09 | 1993-04-27 | Morton Shulman | Pain controlling composition and method of preparation |
| US5635540A (en) * | 1994-12-09 | 1997-06-03 | The University Of Virginia Patent Foundation | Stabilized topical pharmaceutical preparations |
| US6077545A (en) | 1995-10-30 | 2000-06-20 | Matrix Pharmaceuticals, Inc. | Process and composition for therapeutic cisplatin (CDDP) |
| ES2341399T3 (es) * | 1996-03-26 | 2010-06-18 | Eli Lilly And Company | Benziotofenos, formulaciones que contienen los mismos y procedimientos. |
| US6541021B1 (en) * | 1999-03-18 | 2003-04-01 | Durect Corporation | Devices and methods for pain management |
| US6835194B2 (en) * | 1999-03-18 | 2004-12-28 | Durect Corporation | Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners |
| US7074803B2 (en) * | 2001-03-02 | 2006-07-11 | Durect Corporation | Opioid formulations |
| JP2004527573A (ja) * | 2001-04-24 | 2004-09-09 | パーデュー・リサーチ・ファウンデーション | 哺乳類の神経組織損傷の治療のための方法及び組成物 |
| AU2003211009A1 (en) * | 2002-02-11 | 2003-09-04 | Wake Forest University | Compositions and methods for treating pain using cyclooxygenase-1 inhibitors |
| US7838034B2 (en) | 2002-07-30 | 2010-11-23 | Grunenthal Gmbh | Intravenous pharmaceutical form of administration |
| DE10234784A1 (de) * | 2002-07-30 | 2004-02-19 | Günenthal GmbH | Intravenös applizierbare, pharmazeutische Darreichungsform |
| US20040102476A1 (en) * | 2002-11-25 | 2004-05-27 | Chan Tai Wah | High concentration formulations of opioids and opioid derivatives |
| JP4686361B2 (ja) * | 2002-12-31 | 2011-05-25 | アルタス ファーマシューティカルズ インコーポレイテッド | ヒト成長ホルモンの結晶およびその調製方法 |
| WO2004060920A1 (en) * | 2002-12-31 | 2004-07-22 | Altus Pharmaceuticals Inc. | Complexes of protein crystals and ionic polymers |
| GB0300531D0 (en) | 2003-01-10 | 2003-02-12 | West Pharm Serv Drug Res Ltd | Pharmaceutical compositions |
| WO2007076131A2 (en) * | 2005-12-23 | 2007-07-05 | Altus Pharmaceuticals Inc. | Compositions comprising polycation-complexed protein crystals and methods of treatment using them |
| JP2010513309A (ja) * | 2006-12-18 | 2010-04-30 | アルタス ファーマシューティカルズ インコーポレイテッド | ヒト成長ホルモン製剤 |
| FI20075091A0 (fi) * | 2007-02-09 | 2007-02-09 | Kim Lemberg | Noroksimorfoni käytettäväksi lääkeaineena |
| US20080227805A1 (en) * | 2007-02-28 | 2008-09-18 | Abbott Laboratories | Sustained release parenteral formulations of buprenorphine |
| US9125867B2 (en) * | 2010-02-24 | 2015-09-08 | Invincible Biotechnology | Diversion- and/or abuse-resistant compositions and methods for making the same |
| GB2513060B (en) * | 2010-06-08 | 2015-01-07 | Rb Pharmaceuticals Ltd | Microparticle buprenorphine suspension |
| US9272044B2 (en) | 2010-06-08 | 2016-03-01 | Indivior Uk Limited | Injectable flowable composition buprenorphine |
| GB201404139D0 (en) | 2014-03-10 | 2014-04-23 | Rb Pharmaceuticals Ltd | Sustained release buprenorphine solution formulations |
| AU2015341490C1 (en) | 2014-11-07 | 2021-03-11 | Indivior Uk Limited | Buprenorphine dosing regimens |
| US10646484B2 (en) | 2017-06-16 | 2020-05-12 | Indivior Uk Limited | Methods to treat opioid use disorder |
| WO2022175977A1 (en) * | 2021-02-18 | 2022-08-25 | Navin Saxena Research And Technology Private Limited | A biodegradable implant composition and process for long term delivery of buprenorphine and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB784659A (en) * | 1954-11-26 | 1957-10-16 | Upjohn Co | Therapeutic compositions and aqueous suspensions thereof |
| US3337406A (en) * | 1963-12-12 | 1967-08-22 | Mar Sal Inc | Treatment of arteriosclerotic diseases |
| EP0031603A1 (en) * | 1979-12-31 | 1981-07-08 | American Cyanamid Company | Pharmaceutical composition of matter |
| US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
| US4599354A (en) * | 1985-03-11 | 1986-07-08 | Morton Shulman | Composition and method for producing prolonged pain relief |
-
1990
- 1990-03-20 NL NL9000634A patent/NL9000634A/nl not_active Application Discontinuation
-
1991
- 1991-03-20 JP JP91507032A patent/JPH05507466A/ja active Pending
- 1991-03-20 DE DE69109279T patent/DE69109279T2/de not_active Expired - Fee Related
- 1991-03-20 AT AT91906827T patent/ATE121631T1/de not_active IP Right Cessation
- 1991-03-20 CA CA002077641A patent/CA2077641C/en not_active Expired - Fee Related
- 1991-03-20 EP EP91906827A patent/EP0521070B1/en not_active Expired - Lifetime
- 1991-03-20 WO PCT/NL1991/000042 patent/WO1991014455A1/en active IP Right Grant
- 1991-03-20 ES ES91906827T patent/ES2074269T3/es not_active Expired - Lifetime
- 1991-03-20 AU AU75580/91A patent/AU646857B2/en not_active Ceased
- 1991-03-20 DK DK91906827.0T patent/DK0521070T3/da active
-
1992
- 1992-09-03 NO NO923429A patent/NO300114B1/no unknown
- 1992-09-08 FI FI924019A patent/FI98890C/fi not_active IP Right Cessation
- 1992-11-20 US US07/979,128 patent/US5346903A/en not_active Expired - Lifetime
-
1995
- 1995-04-27 GR GR950400877T patent/GR3015940T3/el unknown
-
1997
- 1997-05-13 BR BR1100601-3A patent/BR1100601A/pt active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| BR1100601A (pt) | 2000-04-18 |
| NO923429L (no) | 1992-09-17 |
| CA2077641C (en) | 2001-07-03 |
| JPH05507466A (ja) | 1993-10-28 |
| AU646857B2 (en) | 1994-03-10 |
| FI98890B (fi) | 1997-05-30 |
| EP0521070B1 (en) | 1995-04-26 |
| CA2077641A1 (en) | 1991-09-21 |
| WO1991014455A1 (en) | 1991-10-03 |
| FI924019A0 (fi) | 1992-09-08 |
| DE69109279D1 (de) | 1995-06-01 |
| ATE121631T1 (de) | 1995-05-15 |
| AU7558091A (en) | 1991-10-21 |
| FI924019A (fi) | 1992-09-08 |
| NL9000634A (nl) | 1991-10-16 |
| GR3015940T3 (en) | 1995-07-31 |
| US5346903A (en) | 1994-09-13 |
| EP0521070A1 (en) | 1993-01-07 |
| NO923429D0 (no) | 1992-09-03 |
| FI98890C (fi) | 1997-09-10 |
| DE69109279T2 (de) | 1995-11-09 |
| DK0521070T3 (da) | 1995-05-22 |
| ES2074269T3 (es) | 1995-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO300114B1 (no) | Fremgangsmåte for fremstilling av et vandig suspensjonspreparat for injeksjon | |
| JP4012328B2 (ja) | エデテートを含有する水中油滴エマルジョン | |
| AU2001266896B2 (en) | Improved injectable dispersions of propofol | |
| KR102055937B1 (ko) | 불용성 코르티코스테로이드 및 수용성 코르티코스테로이드를 포함하는 약학적 제형 | |
| JP2004516265A (ja) | 強化された微生物阻害を有するプロポフォール製剤 | |
| JP2002523356A (ja) | プロポフォールの注射可能水性分散物 | |
| AU6159600A (en) | Moxifloxacin formulation containing common salt | |
| TWI674899B (zh) | 醫藥配方 | |
| JP2012116860A (ja) | ミセル | |
| EP0824916B1 (en) | Pranoprofen eyedrops containing organic amine | |
| KR20120087902A (ko) | ｐＨ 조절제를 포함하는 탁산의 약학적 용액 및 이의 제조 방법 | |
| Ticho et al. | Piloplex, a new long-acting pilocarpine polymer salt. A: Long-term study. | |
| US5709883A (en) | Long acting narcotic analgesics and antagonists | |
| JPH064534B2 (ja) | 長期間の疼痛緩和をもたらす配合剤 | |
| JP2529055B2 (ja) | 苦痛抑制組成物及び調製法 | |
| EP0859597A1 (en) | Sustained release delivery system and long acting narcotic analgesics and antagonists | |
| EP0694300A1 (en) | Treatment of impotence | |
| ES et al. | AQUEOUS SUSPENSION PREPARATION FOR INJECTION, METHOD FOR PRODUCING THE SAME AND USE THEREOF FOR PRODUCING PAIN RELIEF. | |
| JP4472175B2 (ja) | プロスタグランジンおよびベンジルアルコールを含む液剤 | |
| JP2002541087A (ja) | 防腐添加剤を含有するプロポフォール組成物 | |
| EP0656777B1 (de) | Spritzfertige azosemid-injektionslösungen | |
| CA1098039A (en) | Intravenous solutions with antimicrobial agent | |
| Payá et al. | AS-OCT of cyclitic membrane pre and post treatment with rtPA in the anterior chamber | |
| CN117100784A (zh) | 一种无针注射用中药组合物及其制备方法 |